USD 1.31
↓ -0.1 (-7.04%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| ALLR | -7.0 | -7.1 | -21.1 | -73.2 | -93.6 | -99.6 | -100.0 | -100.0 | -100.0 | -100.0 |
| S&P 500 | -0.7 | -1.2 | 1.6 | 6.5 | 11.3 | 31.2 | 26.1 | 89.3 | 189.3 | 33342.9 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | ALLR |
| name | Allarity Therapeutics, Inc. |
| price | 1.31 |
| changes percentage | -7.04 |
| change | -0.10 |
| day low | 1.27 |
| day high | 1.40 |
| year high | 666 |
| year low | 1.26 |
| market cap | 1850572 |
| price avg 50 | 1.99 |
| price avg 200 | 61.09 |
| exchange | NASDAQ |
| volume | 111446 |
| avg volume | 573913 |
| open | 1.40 |
| previous close | 1.41 |
| eps | -10.98 |
| pe | -0.12 |
| earnings announcement | 2024-11-12T05:00:00.000+0000 |
| shares outstanding | 1412650 |
| timestamp | 2024-11-15 14:47:15 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001860657 | |||
| revenue | 0 | 0 | NaN |
| gross profit | -37000 | -120000 | 69.17 |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 7866000 | 6930000 | 13.51 |
| operating expenses | 17892000 | 16892000 | 5.92 |
| interest income | 22000 | 30000 | -26.67 |
| interest expense | 498000 | 223000 | 123.32 |
| ebitda | -12083000 | -17236000 | 29.90 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -17929000 | -34463000 | 47.98 |
| operating income ratio | 0 | 0 | NaN |
| net income | -11901000 | -16058000 | 25.89 |
| net income ratio | 0 | 0 | NaN |
| eps | -205.11 | -47194.16 | 99.57 |
Gross Profit: Gross Profit increased to 0 million in 2023 from 0 million in 2022 representing a change of 69.17%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 8 million in 2023 from 7 million in 2022 representing a change of 13.51%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Earnings per Share (EPS): EPS increased to -205.11 in 2023 from -205.11 in 2022 representing a change of 99.57%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Operating Expenses: Operating Expenses increased to 18 million in 2023 from 17 million in 2022 representing a change of 5.92%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -12 million in 2023 from -17 million in 2022 representing a change of 29.9%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -18 million in 2023 from -34 million in 2022 representing a change of 47.98%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -12 million in 2023 from -16 million in 2022 representing a change of 25.89%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001860657 | |||
| revenue | 0 | 0 | NaN |
| gross profit | 0 | -1000 | 100.00 |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 1021000 | 1058000 | -3.50 |
| operating expenses | 12313000 | 3371000 | 265.26 |
| interest income | 261000 | 53000 | 392.45 |
| interest expense | -50000 | 426000 | -111.74 |
| ebitda | -12313000 | -1202000 | -924.38 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -12313000 | -3371000 | -265.26 |
| operating income ratio | 0 | 0 | NaN |
| net income | -12152000 | -1629000 | -645.98 |
| net income ratio | 0 | 0 | NaN |
| eps | -0.77 | -0.11 | -600.00 |
Gross Profit: Gross Profit increased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of 100.0%. This indicates a sales profitability growth, which is a positive sign for the company.
Operating Expenses: Operating Expenses decreased to 12 million in 2024Q3 from 3 million in 2024Q2 representing a change of 265.26%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -12 million in 2024Q3 from -1 million in 2024Q2 representing a change of -924.38%. The increase in EBITDA indicates improved operational efficiency and profitability.
Research and Development (R&D) Expenses: R&D Expenses decreased to 1 million in 2024Q3 from 1 million in 2024Q2 representing a change of -3.5%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Income: Operating income decreased to -12 million in 2024Q3 from -3 million in 2024Q2 representing a change of -265.26%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -12 million in 2024Q3 from -2 million in 2024Q2 representing a change of -645.98%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -0.77 in 2024Q3 from -0.77 in 2024Q2 representing a change of -600.0%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001860657 | |||
| total assets | 11862000 | 14544000 | -18.44 |
| total liabilities | 14613000 | 12654000 | 15.48 |
| total equity | -2751000 | 1890000 | -245.56 |
| cash and cash equivalents | 166000 | 2029000 | -91.82 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 1971000 | 4968000 | -60.33 |
| total non current assets | 9891000 | 9576000 | 3.29 |
| total current liabilities | 14167000 | 11222000 | 26.24 |
| total non current liabilities | 446000 | 1432000 | -68.85 |
| common stock | 0 | 2000 | -100.00 |
| retained earnings | -94451000 | -82550000 | -14.42 |
| total debt | 1300000 | 3735000 | -65.19 |
Total Assets: Total Assets decreased to 12 million in 2023 from 15 million in 2022 representing a change of -18.44%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 15 million in 2023 from 13 million in 2022 representing a change of 15.48%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to -3 million in 2023 from 2 million in 2022 representing a change of -245.56%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 0 million in 2023 from 2 million in 2022 representing a change of -91.82%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 2 million in 2023 from 5 million in 2022 representing a change of -60.33%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 14 million in 2023 from 11 million in 2022 representing a change of 26.24%. This indicates a higher short-term debt burden.
Common Stock: Common Stock decreased to 0 in 2023 from 0 in 2022 representing a change of -100.0%. This indicates a decrease in ownership interest.
Retained Earnings: Retained Earnings decreased to -94 million in 2023 from -83 million in 2022 representing a change of -14.42%. This indicates an accumulated losses.
Total Debt: Total Debt decreased to 1 million in 2023 from 4 million in 2022 representing a change of -65.19%. This indicates a reduction in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001860657 | |||
| total assets | 20378000 | 30883000 | -34.02 |
| total liabilities | 7414000 | 11048000 | -32.89 |
| total equity | 12964000 | 19835000 | -34.64 |
| cash and cash equivalents | 18463000 | 19233000 | -4.00 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 20366000 | 21309000 | -4.43 |
| total non current assets | 12000 | 9574000 | -99.87 |
| total current liabilities | 7414000 | 10616000 | -30.16 |
| total non current liabilities | 0 | 432000 | -100.00 |
| common stock | 0 | 3000 | -100.00 |
| retained earnings | -111513000 | -99923000 | -11.60 |
| total debt | 0 | 1325000 | -100.00 |
Total Assets: Total Assets decreased to 20 million in 2024Q3 from 31 million in 2024Q2 representing a change of -34.02%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 13 million in 2024Q3 from 20 million in 2024Q2 representing a change of -34.64%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 18 million in 2024Q3 from 19 million in 2024Q2 representing a change of -4.0%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 20 million in 2024Q3 from 21 million in 2024Q2 representing a change of -4.43%. This indicates a worsen liquidity position.
Common Stock: Common Stock decreased to 0 in 2024Q3 from 0 in 2024Q2 representing a change of -100.0%. This indicates a decrease in ownership interest.
Retained Earnings: Retained Earnings decreased to -112 million in 2024Q3 from -100 million in 2024Q2 representing a change of -11.6%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 7 million in 2024Q3 from 11 million in 2024Q2 representing a change of -32.89%. This indicates a decrease in overall liabilities.
Total Current Liabilities: Total Current Liabilities decreased to 7 million in 2024Q3 from 11 million in 2024Q2 representing a change of -30.16%. This indicates a lower short-term debt burden.
Total Debt: Total Debt decreased to 0 million in 2024Q3 from 1 million in 2024Q2 representing a change of -100.0%. This indicates a reduction in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001860657 | |||
| net change in cash | -1863000 | -17526000 | 89.37 |
| operating cash flow | -12745000 | -16817000 | 24.21 |
| free cash flow | -12745000 | -16835000 | 24.29 |
| capital expenditure | 0 | -18000 | 100.00 |
| depreciation and amortization | 37000 | 60000 | -38.33 |
| deferred income tax | 97000 | -1612000 | 106.02 |
| stock based compensation | -71000 | 1752000 | -104.05 |
| accounts payables | 2165000 | 6207000 | -65.12 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 0 | -18000 | 100.00 |
| net cash used for investing activites | 0 | 791000 | -100.00 |
| debt repayment | -2649000 | 1000000 | -364.90 |
| common stock issued | 20298000 | 0 | NaN |
| common stock repurchased | -6654000 | -1511000 | -340.37 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 10995000 | -1311000 | 938.67 |
| cash at end of period | 166000 | 2029000 | -91.82 |
| accounts receivables | 0 | 0 | NaN |
| cash at beginning of period | 2029000 | 19555000 | -89.62 |
Net Change in Cash: Net Change in Cash increased to -2 million in 2023 from -18 million in 2022 representing a change of 89.37%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -13 million in 2023 from -17 million in 2022 representing a change of 24.21%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -13 million in 2023 from -17 million in 2022 representing a change of 24.29%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 0 million in 2023 from 2 million in 2022 representing a change of -104.05%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 2 million in 2023 from 6 million in 2022 representing a change of -65.12%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Capital Expenditure: Capital Expenditure increased to 0 million in 2023 from 0 million in 2022 representing a change of 100.0%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Deferred Income Tax: Deferred Income Tax increased to 0 million in 2023 from -2 million in 2022 representing a change of 106.02%. This indicates that the company's tax liability for future periods has increased.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001860657 | |||
| operating cash flow | -5443000 | -7216000 | 24.57 |
| free cash flow | -5443000 | -7216000 | 24.57 |
| capital expenditure | 0 | 0 | NaN |
| depreciation and amortization | 5000 | 1000 | 400.00 |
| deferred income tax | -432000 | 0 | NaN |
| stock based compensation | 17000 | 111000 | -84.68 |
| accounts receivables | 764000 | -248000 | 408.06 |
| accounts payables | -3050000 | -3411000 | 10.58 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 0 | 0 | NaN |
| net cash used for investing activites | 0 | 0 | NaN |
| debt repayment | 0 | -1340000 | 100.00 |
| common stock issued | 5430000 | 27649000 | -80.36 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | -71000 | 0 | NaN |
| net cash used provided by financing activities | 4868000 | 26309000 | -81.50 |
| net change in cash | -770000 | 18921000 | -104.07 |
| cash at end of period | 18463000 | 19233000 | -4.00 |
| cash at beginning of period | 19233000 | 312000 | 6,064.42 |
Net Change in Cash: Net Change in Cash decreased to -1 million in 2024Q3 from 19 million in 2024Q2 representing a change of -104.07%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Accounts Receivables: Accounts Receivables increased to 1 in 2024Q3 from 0 million in 2024Q2 representing a change of 408.06%. This suggests that the company is less capable of collecting payments from its customers.
Dividends Paid: Dividends Paid decreased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of nan%. This indicates a weaker financial position, less confidence in future prospects, and a reluctance to return value to shareholders.
Operating Cash Flow: Operating Cash Flow increased to -5 million in 2024Q3 from -7 million in 2024Q2 representing a change of 24.57%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -5 million in 2024Q3 from -7 million in 2024Q2 representing a change of 24.57%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of -84.68%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 3 million in 2024Q3 from 3 million in 2024Q2 representing a change of 10.58%. This indicates that the company has reduced its outstanding obligations to its suppliers.
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -119.56 | -47194.16 | 99.75 |
| operating cash flow per share | -128.04 | -49424.85 | 99.74 |
| free cash flow per share | -128.04 | -49477.75 | 99.74 |
| cash per share | 1.67 | 5963.19 | -99.97 |
| book value per share | -27.64 | 5554.67 | -100.50 |
| tangible book value per share | -126.81 | -22509.66 | 99.44 |
| shareholders equity per share | -27.64 | 5554.67 | -100.50 |
| interest debt per share | 18.06 | 11632.49 | -99.84 |
| market cap | 32912904.42 | 83971955.3 | -60.80 |
| enterprise value | 34046904.42 | 85677955.3 | -60.26 |
| pe ratio | -2.77 | -5.23 | 47.11 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -2.58 | -4.99 | 48.28 |
| pfcf ratio | -2.58 | -4.99 | 48.23 |
| pb ratio | -11.96 | 44.43 | -126.93 |
| ptb ratio | -11.96 | 44.43 | -126.93 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -2.82 | -4.97 | 43.31 |
| ev to operating cash flow | -2.67 | -5.09 | 47.57 |
| ev to free cash flow | -2.67 | -5.09 | 47.51 |
| earnings yield | -0.36 | -0.19 | -89.09 |
| free cash flow yield | -0.39 | -0.2 | -93.15 |
| debt to equity | -0.47 | 1.98 | -123.91 |
| debt to assets | 0.11 | 0.26 | -57.32 |
| net debt to ebitda | -0.09 | -0.1 | 5.18 |
| current ratio | 0.14 | 0.44 | -68.57 |
| interest coverage | -36.0 | -154.54 | 76.70 |
| income quality | 1.07 | 1.05 | 2.26 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0.83 | 0.66 | 26.74 |
| capex to operating cash flow | 0 | -0.0 | 100.00 |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0 | 0.3 | -100.00 |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 272.67 | 76800.62 | -99.64 |
| roic | 11.65 | -5.6 | 308.24 |
| return on tangible assets | -5.98 | -3.21 | -85.93 |
| graham net net | -138.01 | -29306.79 | 99.53 |
| working capital | -12196000 | -6254000 | -95.01 |
| tangible asset value | -12622000 | -7659000 | -64.80 |
| net current asset value | -12642000 | -7686000 | -64.48 |
| invested capital | -2305000 | 3322000 | -169.39 |
| average receivables | 908500 | 1108000 | -18.01 |
| average payables | 7333500 | 3474500 | 111.07 |
| average inventory | 0 | -672500 | 100.00 |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 83022.7 | 19013.46 | 336.65 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0.0 | 0.02 | -77.10 |
| inventory turnover | 0 | 0 | NaN |
| roe | 4.33 | -8.5 | 150.92 |
| capex per share | 0 | 52.9 | -100.00 |
ROE: Return on Equity (ROE) increased to 4.33 on 2023-12-31 from -8.50 on 2022-12-31, representing a change of 150.92%. Suggesting the company has been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -2.77 on 2023-12-31 from -5.23 on 2022-12-31, representing a change of 47.11%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to -0.47 on 2023-12-31 from 1.98 on 2022-12-31, representing a change of -123.91%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Current Ratio: Current Ratio decreased to 0.14 on 2023-12-31 from 0.44 on 2022-12-31, representing a change of -68.57%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Also, it's below 1, indicating potential liquidity issues.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| ALLR | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -0.77 | -0.11 | -609.12 |
| operating cash flow per share | -0.35 | -0.48 | 28.30 |
| free cash flow per share | -0.35 | -0.48 | 28.30 |
| cash per share | 1.17 | 1.28 | -8.75 |
| book value per share | 0.82 | 1.32 | -37.87 |
| tangible book value per share | 0.82 | 0.69 | 19.90 |
| shareholders equity per share | 0.82 | 1.32 | -37.87 |
| interest debt per share | -0.0 | 0.12 | -102.71 |
| market cap | 33248578.2 | 101857846 | -67.36 |
| enterprise value | 14785578.2 | 83949846 | -82.39 |
| pe ratio | -0.68 | -15.63 | 95.62 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -6.11 | -14.12 | 56.73 |
| pfcf ratio | -6.11 | -14.12 | 56.73 |
| pb ratio | 2.56 | 5.14 | -50.06 |
| ptb ratio | 2.56 | 5.14 | -50.06 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -1.2 | -69.84 | 98.28 |
| ev to operating cash flow | -2.72 | -11.63 | 76.65 |
| ev to free cash flow | -2.72 | -11.63 | 76.65 |
| earnings yield | -0.37 | -0.02 | -2,185.33 |
| free cash flow yield | -0.16 | -0.07 | -131.08 |
| debt to equity | 0 | 0.07 | -100.00 |
| debt to assets | 0 | 0.04 | -100.00 |
| net debt to ebitda | 1.5 | 14.9 | -89.94 |
| current ratio | 2.75 | 2.01 | 36.85 |
| interest coverage | 246.26 | -7.91 | 3,212.04 |
| income quality | 0.47 | 4.43 | -89.40 |
| dividend yield | 0.0 | 0 | NaN |
| payout ratio | -0.01 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0 | 0.31 | -100.00 |
| capex to operating cash flow | 0 | 0 | NaN |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0 | 0 | NaN |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 3.78 | 1.8 | 109.90 |
| roic | 0 | -0.16 | 100.00 |
| return on tangible assets | -0.6 | -0.08 | -680.68 |
| graham net net | 0.7 | 0.63 | 12.10 |
| working capital | 12952000 | 10693000 | 21.13 |
| tangible asset value | 12964000 | 10278000 | 26.13 |
| net current asset value | 12952000 | 10261000 | 26.23 |
| invested capital | 12964000 | 20267000 | -36.03 |
| average receivables | 789500 | 1455000 | -45.74 |
| average payables | 6223000 | 9405500 | -33.84 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 0 | 697770 | -100.00 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0 | 0.0 | -100.00 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.94 | -0.08 | -1,041.35 |
| capex per share | 0 | 0 | NaN |
ROE: Return on Equity (ROE) decreased to -0.94 on 2024-09-30 Q3 from -0.08 on 2024-06-30 Q2, representing a change of -1041.35%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -0.68 on 2024-09-30 Q3 from -15.63 on 2024-06-30 Q2, representing a change of 95.62%. Indicating an increase in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 2.75 on 2024-09-30 Q3 from 2.01 on 2024-06-30 Q2, representing a change of 36.85%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Also, it's above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.00 on 2024-09-30 Q3 from 0.07 on 2024-06-30 Q2, representing a change of -100.00%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Negative
Publish Date: 2024-11-12 14:41:00
LOS ANGELES--(BUSINESS WIRE)--ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Sentiment: Positive
Publish Date: 2024-11-12 10:30:00
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 24-cv-06952, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Allarity securities between May 17, 2022 and July 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Sentiment: Neutral
Publish Date: 2024-11-12 10:00:00
LOS ANGELES , Nov. 12, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ: ALLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 17, 2022 and July 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before November 12, 2024.
Sentiment: Negative
Publish Date: 2024-11-12 07:00:00
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Allarity securities between May 17, 2022, and July 19, 2024, inclusive (the "Class Period").
Sentiment: Negative
Publish Date: 2024-11-11 15:45:00
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Allarity To Contact Him Directly To Discuss Their Options NEW YORK CITY, NY / ACCESSWIRE / November 11, 2024 / If you suffered losses exceeding $50,000 in Allarity between May 17, 2022 and July 19, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR) and reminds investors of the November 12, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Sentiment: Neutral
Publish Date: 2024-11-11 11:15:00
LOS ANGELES, CA / ACCESSWIRE / November 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 17, 2022 and July 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before November 12, 2024.
Sentiment: Negative
Publish Date: 2024-11-11 07:00:00
NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Allarity securities between May 17, 2022, and July 19, 2024, inclusive (the "Class Period").
Sentiment: Positive
Publish Date: 2024-11-10 12:00:00
NEW YORK , Nov. 10, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 24-cv-06952, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Allarity securities between May 17, 2022 and July 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Sentiment: Positive
Publish Date: 2024-11-10 11:50:00
LOS ANGELES, CA / ACCESSWIRE / November 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 17, 2022 and July 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before November 12, 2024.
Sentiment: Negative
Publish Date: 2024-11-10 07:00:00
NEW YORK, NY / ACCESSWIRE / November 10, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Allarity securities between May 17, 2022, and July 19, 2024, inclusive (the "Class Period").
Sentiment: Negative
Publish Date: 2024-11-09 12:30:00
LOS ANGELES, CA / ACCESSWIRE / November 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 17, 2022 and July 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before November 12, 2024.
Sentiment: Positive
Publish Date: 2024-11-09 08:32:00
NEW YORK, Nov. 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline.
Sentiment: Neutral
Publish Date: 2024-11-08 19:00:00
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers and acquirers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline. Allarity is a clinical-stage biopharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Fi.
Sentiment: Positive
Publish Date: 2024-11-08 16:00:00
NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Allarity Therapeutics, Inc. (“Allarity” or “the Company”) (NASDAQ: ALLR) and certain of its officers.
Sentiment: Negative
Publish Date: 2024-11-08 13:39:00
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 12, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) securities between May 17, 2022 and July 19, 2024, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On February 6, 2023, Allarity disclosed that it had.
Sentiment: Positive
Publish Date: 2024-11-08 12:00:00
NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 24-cv-06952, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Allarity securities between May 17, 2022 and July 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Sentiment: Negative
Publish Date: 2024-11-08 11:00:00
LOS ANGELES, CA / ACCESSWIRE / November 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 17, 2022 and July 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before November 12, 2024.
Sentiment: Negative
Publish Date: 2024-11-08 09:45:00
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Allarity To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Allarity between May 17, 2022 and July 19, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Nov. 8, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR) and reminds investors of the November 12, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Sentiment: Negative
Publish Date: 2024-11-08 07:00:00
NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Allarity securities between May 17, 2022, and July 19, 2024, inclusive (the "Class Period").
Sentiment: Positive
Publish Date: 2024-11-07 20:36:00
NEW YORK , Nov. 7, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the "Class Period"), of the important November 12, 2024 lead plaintiff deadline. So what: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
